{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,31]],"date-time":"2026-08-31T21:43:00Z","timestamp":1788212580456,"version":"build-2803163510"},"reference-count":28,"publisher":"Oxford University Press (OUP)","issue":"6","license":[{"start":{"date-parts":[[2025,11,26]],"date-time":"2025-11-26T00:00:00Z","timestamp":1764115200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"funder":[{"name":"University Medicine Essen Clinician Scientist Academy"},{"DOI":"10.13039\/501100001659","name":"German Research Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,11,26]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>Selective RET inhibition with selpercatinib significantly improved outcomes in advanced RET-mutant medullary thyroid cancer (MTC). However, data from endocrine oncology practice are limited, particularly in heterogeneous treatment-naive and pretreated patients. Evaluating real-world effectiveness and safety is essential to reaffirm clinical trial results.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Design<\/jats:title>\n                    <jats:p>Retrospective, single-center study.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We analyzed patients with RET-mutant MTC treated with selpercatinib between March 2021 and May 2025 at the Essen Endocrine Tumor Center. Clinical characteristics, treatment outcomes as well as frequency and longitudinal course of adverse events (AEs) were assessed.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Thirty-one patients with advanced RET-mutant MTC (87% with distant metastases; median age 54 years; 84% sporadic) were included. First-line selpercatinib (52%) treatment resulted in significantly longer median progression-free survival (PFS) (not reached vs. 18.3 months) and higher objective response rate (ORR) (81% vs. 33%) compared to later-line use. One-year PFS rate was 100% for first-line and 60% for further-line treatment. ORR was significantly higher in patients without bone metastases (90% vs 43%). Age at treatment initiation, sex, and RET mutation subtype did not impact ORR or PFS. The most common AEs included hypertension (58.6%) and erectile dysfunction (55.6%). Grade \u22653 events occurred in 37.5% of patients, with hypertension most frequent. Treatment interruptions and dose reductions were required in 22.6% of patients, primarily due to QTc prolongation and fatigue. Three patients (9.7%) discontinued treatment permanently due to AEs.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>In real-word settings, selpercatinib showed high efficacy and tolerability, particularly as first-line treatment. Our findings support its use as the preferred initial targeted treatment for RET-driven MTC beyond clinical trial populations.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/ejendo\/lvaf256","type":"journal-article","created":{"date-parts":[[2025,12,19]],"date-time":"2025-12-19T13:00:59Z","timestamp":1766149259000},"page":"762-771","source":"Crossref","is-referenced-by-count":2,"title":["Real-world efficacy and safety of selpercatinib in\n                    <i>RET<\/i>\n                    -mutant medullary thyroid cancer at a Tertiary Referral Center"],"prefix":"10.1093","volume":"193","author":[{"ORCID":"https:\/\/orcid.org\/0009-0001-9441-3046","authenticated-orcid":false,"given":"Yara Maria","family":"Machlah","sequence":"first","affiliation":[{"name":"Department of Endocrinology, Diabetes and Metabolism, University Hospital Essen, University of Duisburg-Essen , Essen 45147 ,","place":["Germany"]},{"name":"Endocrine Tumor Center and ENETS Center at West German Cancer Center (WTZ), Member of ENDO-ERN and EURACAN , Essen 45147 ,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lynn Marlene","family":"Srasra","sequence":"additional","affiliation":[{"name":"Department of Endocrinology, Diabetes and Metabolism, University Hospital Essen, University of Duisburg-Essen , Essen 45147 ,","place":["Germany"]},{"name":"Endocrine Tumor Center and ENETS Center at West German Cancer Center (WTZ), Member of ENDO-ERN and EURACAN , Essen 45147 ,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"Theurer","sequence":"additional","affiliation":[{"name":"Endocrine Tumor Center and ENETS Center at West German Cancer Center (WTZ), Member of ENDO-ERN and EURACAN , Essen 45147 ,","place":["Germany"]},{"name":"Institute of Pathology, University Hospital Essen, University of Duisburg-Essen , Essen 45147 ,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frank","family":"Weber","sequence":"additional","affiliation":[{"name":"Endocrine Tumor Center and ENETS Center at West German Cancer Center (WTZ), Member of ENDO-ERN and EURACAN , Essen 45147 ,","place":["Germany"]},{"name":"Department of General, Visceral and Transplantation Surgery, Division of Endocrine Surgery, University Hospital Essen, University of Duisburg-Essen , Essen 45147 ,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Harald","family":"Lahner","sequence":"additional","affiliation":[{"name":"Department of Endocrinology, Diabetes and Metabolism, University Hospital Essen, University of Duisburg-Essen , Essen 45147 ,","place":["Germany"]},{"name":"Endocrine Tumor Center and ENETS Center at West German Cancer Center (WTZ), Member of ENDO-ERN and EURACAN , Essen 45147 ,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0357-4192","authenticated-orcid":false,"given":"Dagmar","family":"F\u00fchrer","sequence":"additional","affiliation":[{"name":"Department of Endocrinology, Diabetes and Metabolism, University Hospital Essen, University of Duisburg-Essen , Essen 45147 ,","place":["Germany"]},{"name":"Endocrine Tumor Center and ENETS Center at West German Cancer Center (WTZ), Member of ENDO-ERN and EURACAN , Essen 45147 ,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2904-4341","authenticated-orcid":false,"given":"Tim","family":"Brandenburg","sequence":"additional","affiliation":[{"name":"Department of Endocrinology, Diabetes and Metabolism, University Hospital Essen, University of Duisburg-Essen , Essen 45147 ,","place":["Germany"]},{"name":"Endocrine Tumor Center and ENETS Center at West German Cancer Center (WTZ), Member of ENDO-ERN and EURACAN , Essen 45147 ,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2025,12,22]]},"reference":[{"issue":"9","key":"2026010203112266500_lvaf256-B1","doi-asserted-by":"publisher","first-page":"2134","DOI":"10.1002\/cncr.22244","article-title":"Prognosis of medullary thyroid carcinoma: demographic, clinical, and pathologic predictors of survival in 1252 cases","volume":"107","author":"Roman","year":"2006","journal-title":"Cancer"},{"issue":"2","key":"2026010203112266500_lvaf256-B2","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1200\/JCO.2011.35.5040","article-title":"Vandetanib in patients with locally advanced or metastatic medullary thyroid cancer: a randomized, double-blind phase III trial","volume":"30","author":"Wells","year":"2012","journal-title":"J Clin Oncol"},{"issue":"29","key":"2026010203112266500_lvaf256-B3","doi-asserted-by":"publisher","first-page":"3639","DOI":"10.1200\/JCO.2012.48.4659","article-title":"Cabozantinib in progressive medullary thyroid cancer","volume":"31","author":"Elisei","year":"2013","journal-title":"J Clin Oncol"},{"issue":"1","key":"2026010203112266500_lvaf256-B4","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1159\/000336977","article-title":"2012 European thyroid association guidelines for metastatic medullary thyroid cancer","volume":"1","author":"Schlumberger","year":"2012","journal-title":"Eur Thyroid J"},{"issue":"6","key":"2026010203112266500_lvaf256-B5","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1089\/thy.2014.0335","article-title":"Revised American Thyroid Association guidelines for the management of medullary thyroid carcinoma","volume":"25","author":"Wells","year":"2015","journal-title":"Thyroid"},{"issue":"6","key":"2026010203112266500_lvaf256-B6","doi-asserted-by":"publisher","first-page":"633","DOI":"10.1530\/ERC-18-0056","article-title":"Clinical significance of RET and RAS mutations in sporadic medullary thyroid carcinoma: a meta-analysis","volume":"25","author":"Vuong","year":"2018","journal-title":"Endocr Relat Cancer"},{"key":"2026010203112266500_lvaf256-B7","doi-asserted-by":"publisher","first-page":"324","DOI":"10.1016\/j.isci.2019.09.030","article-title":"Genetic landscape of somatic mutations in a large cohort of sporadic medullary thyroid carcinomas studied by next-generation targeted sequencing","volume":"20","author":"Ciampi","year":"2019","journal-title":"iScience"},{"issue":"7","key":"2026010203112266500_lvaf256-B8","doi-asserted-by":"publisher","first-page":"836","DOI":"10.1158\/2159-8290.CD-18-0338","article-title":"Precision targeted therapy with BLU-667 for RET-driven cancers","volume":"8","author":"Subbiah","year":"2018","journal-title":"Cancer Discov"},{"issue":"6","key":"2026010203112266500_lvaf256-B9","doi-asserted-by":"publisher","first-page":"662","DOI":"10.1038\/s41587-020-0568-2","article-title":"FDA approves first RET inhibitor","volume":"38","author":"Harrison","year":"2020","journal-title":"Nat Biotechnol."},{"issue":"9","key":"2026010203112266500_lvaf256-B10","doi-asserted-by":"publisher","first-page":"825","DOI":"10.1056\/NEJMoa2005651","article-title":"Efficacy of selpercatinib in RET-altered thyroid cancers","volume":"383","author":"Wirth","year":"2020","journal-title":"N Engl J Med"},{"key":"2026010203112266500_lvaf256-B11","volume-title":"Retsevmo Selpercatinib","author":"Agency","year":"2025"},{"key":"2026010203112266500_lvaf256-B12","doi-asserted-by":"publisher","first-page":"S1299","DOI":"10.1016\/j.annonc.2022.07.1736","article-title":"1656P durable efficacy of selpercatinib in patients (pts) with medullary thyroid cancer (MTC): update of the LIBRETTO-001 trial","volume":"33","author":"Kroiss","year":"2022","journal-title":"Ann Oncol."},{"issue":"20","key":"2026010203112266500_lvaf256-B13","doi-asserted-by":"publisher","first-page":"1851","DOI":"10.1056\/NEJMoa2309719","article-title":"Phase 3 trial of selpercatinib in advanced RET-mutant medullary thyroid cancer","volume":"389","author":"Hadoux","year":"2023","journal-title":"N Engl J Med"},{"key":"2026010203112266500_lvaf256-B14","volume-title":"TNM Classification of Malignant Tumours Eighth Edition","author":"Brierley","year":"2017"},{"key":"2026010203112266500_lvaf256-B15","doi-asserted-by":"crossref","unstructured":"Machlah YM, Srasra LM, Theurer S, et al \u00a0Supplemental_Materials real-world efficacy and safety of selpercatinib in RET-Mutant medullary thyroid cancer at a Tertiary Referral Center. Figshare; 2025.","DOI":"10.1093\/ejendo\/lvaf256"},{"issue":"1","key":"2026010203112266500_lvaf256-B16","doi-asserted-by":"publisher","first-page":"140","DOI":"10.3390\/cancers16010140","article-title":"Comparative effectiveness of first-line selpercatinib versus standard therapies in patients with RET-activated cancers: an exploratory interpatient analysis of LIBRETTO-001","volume":"16","author":"De Braud","year":"2024","journal-title":"Cancers (Basel)"},{"issue":"22","key":"2026010203112266500_lvaf256-B17","doi-asserted-by":"publisher","first-page":"3835","DOI":"10.3390\/cancers16223835","article-title":"Real-world outcomes of selective RET inhibitor selpercatinib in the United States: descriptive, retrospective findings from two databases","volume":"16","author":"Liao","year":"2024","journal-title":"Cancers (Basel)"},{"issue":"4","key":"2026010203112266500_lvaf256-B18","doi-asserted-by":"publisher","first-page":"1254","DOI":"10.1210\/jc.2016-3906","article-title":"Skeletal complications and mortality in thyroid cancer: a population-based study","volume":"102","author":"Choksi","year":"2017","journal-title":"J Clin Endocrinol Metab"},{"issue":"3","key":"2026010203112266500_lvaf256-B19","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1089\/thy.2020.0206","article-title":"Real-world efficacy and safety of cabozantinib and vandetanib in advanced medullary thyroid cancer","volume":"31","author":"Koehler","year":"2021","journal-title":"Thyroid"},{"issue":"1","key":"2026010203112266500_lvaf256-B20","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1210\/clinem\/dgaf286","article-title":"Comprehensive assessment of multi-kinase inhibitor therapy outcomes in RAIR-(P)DTC and MTC at a tertiary referral centre","volume":"111","author":"Machlah","year":"2025","journal-title":"J Clin Endocrinol Metab"},{"issue":"9","key":"2026010203112266500_lvaf256-B21","doi-asserted-by":"publisher","first-page":"1177","DOI":"10.1089\/thy.2024.0129","article-title":"Erectile dysfunction in patients treated with selpercatinib for RET-altered thyroid cancer","volume":"34","author":"Matrone","year":"2024","journal-title":"Thyroid"},{"issue":"6","key":"2026010203112266500_lvaf256-B22","doi-asserted-by":"publisher","first-page":"e2100496","DOI":"10.1200\/PO.21.00496","article-title":"Selpercatinib-induced hypothyroidism through off-target inhibition of type 2 iodothyronine deiodinase","volume":"6","author":"Boucai","year":"2022","journal-title":"JCO Precis Oncol"},{"issue":"10","key":"2026010203112266500_lvaf256-B23","doi-asserted-by":"publisher","first-page":"1162","DOI":"10.1177\/10507256251367352","article-title":"Patient-reported tolerability of selpercatinib compared to cabozantinib\/vandetanib: a secondary analysis of the LIBRETTO-531 randomized-controlled trial in RET-mutant medullary thyroid cancer","volume":"35","author":"Elisei","year":"2025","journal-title":"Thyroid"},{"issue":"12","key":"2026010203112266500_lvaf256-B24","doi-asserted-by":"publisher","first-page":"1068","DOI":"10.1093\/oncolo\/oyae282","article-title":"Long-term safety of selpercatinib for Rearranged during transfection (RET)-activated advanced solid tumors in LIBRETTO-001: differing patterns of adverse events over time","volume":"29","author":"Raez","year":"2024","journal-title":"Oncologist"},{"issue":"9","key":"2026010203112266500_lvaf256-B25","doi-asserted-by":"publisher","first-page":"1130","DOI":"10.1016\/j.jtho.2022.06.008","article-title":"Brief Report: chylothorax and chylous ascites during RET tyrosine kinase inhibitor therapy","volume":"17","author":"Kalchiem-Dekel","year":"2022","journal-title":"J Thorac Oncol"},{"issue":"6","key":"2026010203112266500_lvaf256-B26","doi-asserted-by":"publisher","first-page":"905","DOI":"10.1530\/EJE-22-0643","article-title":"Chylous effusions in advanced medullary thyroid cancer patients treated with selpercatinib","volume":"187","author":"Prete","year":"2022","journal-title":"Eur J Endocrinol"},{"issue":"9","key":"2026010203112266500_lvaf256-B27","doi-asserted-by":"publisher","first-page":"e3824","DOI":"10.1210\/clinem\/dgac337","article-title":"Selpercatinib treatment of RET-mutated thyroid cancers is associated with gastrointestinal adverse effects","volume":"107","author":"Tsang","year":"2022","journal-title":"J Clin Endocrinol Metab"},{"issue":"5","key":"2026010203112266500_lvaf256-B28","doi-asserted-by":"publisher","first-page":"e240189","DOI":"10.1530\/ETJ-24-0189","article-title":"Fluctuating obliterative bronchiolitis in RET-mutant medullary thyroid cancer patient treated with selpercatinib","volume":"13","author":"Gambale","year":"2024","journal-title":"Eur Thyroid J"}],"container-title":["European Journal of Endocrinology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ejendo\/advance-article-pdf\/doi\/10.1093\/ejendo\/lvaf256\/66110996\/lvaf256.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ejendo\/article-pdf\/193\/6\/762\/66110996\/lvaf256.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ejendo\/article-pdf\/193\/6\/762\/66110996\/lvaf256.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,2]],"date-time":"2026-01-02T08:11:28Z","timestamp":1767341488000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ejendo\/article\/193\/6\/762\/8402220"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,26]]},"references-count":28,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2025,11,26]]}},"URL":"https:\/\/doi.org\/10.1093\/ejendo\/lvaf256","relation":{},"ISSN":["0804-4643","1479-683X"],"issn-type":[{"value":"0804-4643","type":"print"},{"value":"1479-683X","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,12]]},"published":{"date-parts":[[2025,11,26]]}}}